Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of azacitidine, venetoclax combined with gha priming regimen in the treatment of adult refractory and relapsed acute myeloid leukemia: A prospective single-arm multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

HGHui GengGHGuoqiang HuangWZWanhong Zhao

Discussion

Loading...

Member takes

Overview

Prospective study shows 68% complete remission in patients with refractory acute myeloid leukemia, indicating a promising treatment with azacitidine and venetoclax.

Key Points

  • Efficacy led to a complete remission rate of 67.9% after one course in patients with acute myeloid leukemia.
  • A total of 28 patients treated with the combination regimen experienced 100% incidence of hematological adverse reactions.
  • Assessment included treatments over a median of 1 course, with some patients completing 2 courses successfully.
  • The findings indicate that the regimen may enable effective induction remission for refractory acute myeloid leukemia.

Cite This Study

Geng et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3a4https://doi.org/10.1182/blood-2025-1665
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of venetoclax plus CAG (cytarabine, aclarubicin, G-CSF) regimen in patients with relapsed or refractory Acute Myeloid Leukemia: A prospective single-arm phase II study2025
  2. 2The efficacy and safety of venetoclax and azacitidine combined with granulocyte-colony stimulating factor in the treatment of Acute Myeloid Leukemia2025
  3. 3[Clinical Efficacy of CAG Regimen Combined with Venetoclax, Chidamide, and Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia].2025
  4. 4Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study2025
  5. 5Reduced intensive chemotherapy combined with venetoclax in adult patients with Acute Myeloid Leukemia: A retrospective single-center analysis2025